-
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension
07 Apr 2024 12:06 GMT
… messenger RNA (mRNA) – the genetic precursors that encode for disease … of patients with genetic and other diseases.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals (Nasdaq … execute on its “Alnylam P5x25” strategy; Alnylam’s ability to discover …
-
Drug development advances in beneficial loss-of-function (LOF) mutation targets validated by human genetics
26 Mar 2024 17:44 GMT
… pharmaceutical industry. Currently, genetic data and technologies such … Regeneron has partnered with Alnylam to develop an siRNA … disease, and T2D, and Alnylam has utilised its liver … development advances in human genetics-based targets
Article Publication …
-
Alnylam turns to genealogy to find rare disease patients through family trees
26 Mar 2024 14:38 GMT
… on treating some of those genetic diseases, we want to … ’s physician, she received genetic testing that confirmed her own … is home to a genetic population with higher instances of … biobanks and genetic databases have brought patients to Alnylam’s treatments …
-
Alnylam takes a family road trip to talk about health history and heredity in new rare disease campaign
13 Mar 2024 19:35 GMT
Alnylam Pharmaceuticals is hitting the road … families affected by the rare genetic condition to discuss their experiences … a parent who has the genetic variant has a 50% chance …
-
Alnylam embarks on road trip-themed campaign to drive earlier diagnosis of hereditary ATTR amyloidosis
13 Mar 2024 15:51 GMT
… playlist and, according to Alnylam Pharmaceuticals, a thorough conversation … condition in which a genetic variant leads to misfolded … hATTR amyloidosis programs that Alnylam has launched in recent … Road Trip program underscores Alnylam’s commitment to supporting …
-
Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease
13 Mar 2024 11:47 GMT
… was immediately offered a genetic test and finally received … chance of inheriting the genetic variant that causes the … amyloidosis, the role of genetic testing, as well as … com/roadtrip.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals (Nasdaq: ALNY) …
-
Alnylam’s experimental drug for high blood pressure yields encouraging results
05 Mar 2024 18:30 GMT
… to develop and commercialize Alnylam’s zilebesiran for hypertension. … Roche paid Alnylam $310 million upfront, but … correct mistakes in the genetic code that lead to disease … a genetic defect and silence it.
Until zilebesiran, Alnylam has …
-
Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives
05 Mar 2024 12:50 GMT
… messenger RNA (mRNA) – the genetic precursors that encode for disease … of patients with genetic and other diseases.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals (Nasdaq … execute on its “Alnylam P5x25” strategy; Alnylam’s ability to discover …
-
Alnylam to Webcast Presentations at Upcoming March Investor Conferences
27 Feb 2024 13:50 GMT
… being held virtually
Canaccord Genuity “Genetic Medicine for Generalists” on … hours after each event.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals (Nasdaq: ALNY) … scientific possibility into reality. Alnylam’s commercial RNAi therapeutic products …
-
Alnylam stock sinks after last-minute changes in key drug trial
16 Feb 2024 18:44 GMT
… 39;s already underway.
Alnylam (Nasdaq: ALNY) disclosed … a nervous system condition.
Alnylam’s predecessor to vutrisiran … of “clinical meaningfulness.”
Alnylam is headquartered in Cambridge … . Alnylam is developing drugs in four areas: genetic medicines …